Taken together, these observations suggested that PCSK9 inhibition restores the potency of anti‐PD‐1 and promotes the capability of 5‐FU for MSS CRC therapy, indicating two potential combination therapy regimens for MSS CRC, which is of great benefit to MSS CRC patients who account for 95% of metastatic CRC.[46]. This evidence concerns the gene PDCD1 and colorectal carcinoma.